AHA files motions as 340B case returns to district court to determine remedy
Following its unanimous victory in the U.S. Supreme Court earlier this summer, AHA yesterday asked the U.S. District Court for the District of Columbia to order the Department of Health and Human Services to immediately stop underpaying certain hospitals that participate in the 340B Drug Pricing Program and promptly repay them for the unlawful cuts since 2018 without penalizing other hospitals.
Related News Articles
Chairperson's File
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…